****

**Confidence for Translation (C4T) Scheme Application Form 2024**

This scheme is aimed at accelerating translational research projects leading to healthcare impact. This year, projects will be funded primarily from the **UKRI MRC IAA** with contributions from the **Wellcome TPA** and the **NIHR Manchester BRC** budgets at the discretion of the panel.

**Application process:**

1. Before applying, please read the [C4T Application Brief](https://documents.manchester.ac.uk/display.aspx?DocID=49136). You might also want to read the [frequently asked questions](https://documents.manchester.ac.uk/display.aspx?DocID=72621) document.
2. Complete the application form **in the template provided**. **Applicants must complete ALL sections, respecting the word count.** Applications will be anonymised prior to review. To aid in this, all personal information is requested on the first page of the application form as this will be removed prior to review. Please do not include your name or details on your research group in the subsequent questions in the application form. Reference to your previous work should only be on the first page of the form.
3. We **DO NOT require** for the application to be costed by your Research Support Manager/Officer. However, you will need to complete the budget sheet **in the template provided,** outlining your proposed expenditures. In order to do this, you **will need** to use the University [Research Costing Tool BlackDackel](https://www.staffnet.manchester.ac.uk/rbe/rs/research-costing-tool/). Please refer to [this guidance document](https://documents.manchester.ac.uk/protected/display.aspx?DocID=72594) for help with this. Dedicated workshops about the costing process are also available, please refer to the [C4T Application Brief](https://documents.manchester.ac.uk/display.aspx?DocID=49136) and [FAQs document](https://documents.manchester.ac.uk/display.aspx?DocID=72621) for more information. You can request access to BlackDackel by emailing researchcostingtool@manchester.ac.uk.
4. If you are seeking to develop a **small molecule drug** (i.e. non-biologic therapeutic) please ensure the content detailed in the project tractability section of the **MRC DPFS small molecule information form** is clearly covered in the main C4T application form, **OR** [download/complete the form](https://documents.manchester.ac.uk/display.aspx?DocID=72629)and attach it as supplementary information to your application.
5. You are encouraged to attend one of our information workshops to be held via Zoom on **12th June 11:00am-12:00pm** ([Zoom link 1](https://zoom.us/j/92290238662)) or **18th June 10:00-11:00am** ([Zoom link 2](https://zoom.us/j/93196835342)), as well as a dedicated **costings workshop on 25th June, 10:00-11:00** ([Zoom link](https://zoom.us/j/96574982578)). Attendance is not compulsory but strongly advised. These are informal workshops where will be answering any questions on the application and costing process.

**Application deadline: 12 noon, 10th July 2024**

Proposals should be submitted to translation@manchester.ac.uk

Applicants will be notified of the outcome the week commencing the 7th of October 2024. **Projects are expected to start at the end of October 2024 or shortly after and finish by the end of December 2025.**

|  |
| --- |
|  **‘Confidence for Translation’ C4T Award: Full Application Form 2024** |
| **PI details** |
| PI Name |  |
| End date of current contract of employment (only **if the PI is on a fixed term contract**) |  |
| Senior guarantor(only **if the PI is on a fixed term contract)** |  |
| Is the PI a current UoM staff member or holds UoM honorary position? [ ]  UoM Staff [ ]  Honorary position*If honorary status is yet to be officially formalised, please provide details/timelines and name of a UoM Co-I for post award management.* | If *honorary*, please describe status of the contract:[ ]  Current[ ]  In progressIf *in progress*, please provide:Timelines for obtaining:Name of UoM Co-I: |
| PI Faculty |  |
| PI School/Department/Division |  |
| PI Contact Info (email) |  |
| Collaborators: Names / Faculty / School / Division |  |
| Was this project previously (or currently) supported by external or internal funding (including A2E, CiC, IAA, C4T & P4T)?**Yes [ ]  No [ ]**  | *If yes, please provide details on the funder(s) and awards(s) supporting this research:* |
|  |
| References*If you wish to reference your previous work, please add your references here (include doi). Do not reference your own work in the following pages of the application form.* |  |

Please note that this page will be removed from the proposal when it is sent to peer review to keep the review process anonymous. Please do not remove the page break after this text.

|  |
| --- |
| **C4T Project details** |
| Title of Project |  |
| Proposed start date and project duration/end date | *Duration:* |  |
|  | *Start:* |  |
|  | *End:* |  |
| Total funds required100% of directly incurred costs only | *Total:* |  |
|  | *Staff:* |  |
|  | *Consumables:* |  |
|  | *Other (specify):* |  |
| Does your project align with any of the priority areas for the Wellcome trust or NIHR Manchester BRC?**Yes [ ]  No [ ]** If **yes**, please tick all relevant boxes on the right. If BRC alignment is identified, please complete question 17.If **no**, skip this question.*Please note that this information will only be used to assign reviewers and not to determine the source of funding.* ***Proposals focusing outside these priority areas are also welcome and encouraged.****For BRC support we would expect a cross-cluster collaborative project across at least two clusters and evidence of alignment to BRC core strategic aims (details of which can be found in the* [*FAQ*](https://documents.manchester.ac.uk/display.aspx?DocID=72621) *document).* | ***Wellcome’s Health Challenges***[*Read more.*](https://wellcome.org/who-we-are/strategy) | [ ]  Mental Health[ ]  Climate and Health[ ]  Infectious Disease |
|  | ***NIHR Manchester BRC Clusters*** | ***NIHR Manchester BRC*** ***Themes*** |
|  | Cancer | [ ]  Prevention and Early Detection [ ]  Advanced Radiotherapy [ ]  Precision Medicine [ ]  Living with and beyond cancer |
|  | Inflammation | [ ]  Rheumatic Musculoskeletal Diseases [ ]  Respiratory Medicine[ ]  Dermatology: Cutaneous Inflammation and Repair [ ] Integrative Cardiovascular Medicine  |
|  | Disease Complexity and Multi-morbidity | [ ]  Next GenerationPhenotyping and Diagnostics [ ] Next Generation Therapeutics |
|  | High Burden Under researched conditions | [ ]  Hearing Health[ ]  Mental Health[ ]  Rare Conditions |
| 1. Project Summary – please provide a summary of the state of the art leading to this research project including the unmet health, clinical or product development need you are seeking to address. References to be listed in the PI details question on page 2 of this document to keep peer review anonymous. (*Maximum 300 words*)
 |
|  |
| 1. What is your proposed solution to this need? What is the rationale and supporting evidence that your proposed solution will meet the targeted need? You might make use of figures for preliminary data in this box or attached as appendix (these should be under one A4 side). Please avoid using information that might identify you.(*Max 300 words*)
 |
|  |
| 1. Who is the intended end user and/or target market for your proposed innovation? This can be whoever will purchase your product or who will adopt your new intervention or policy. (*Max 200 words*)
 |
|  |
| 1. What are the competing solutions (direct or indirect) and their development status, and what is the competitive advantage of your proposed solution?(*Max 300 words*)
 |
|  |
| 1. How soon would the proposed innovation reach a) patient care or other clinical setting and b) commercial market or other means of distribution? Please explain what additional studies or development work will be required to achieve these endpoints?(*Max 200 words*)
 |
|  |
| 1. Please describe where on the [translational research pathway](http://documents.manchester.ac.uk/display.aspx?DocID=41767) your current research/project sits, and where it aims to go? (e.g. D1 to D2, or T2 to T3)

*(Maximum 100 words)* |
|  |
| 1. What is the specific hurdle or bottleneck that you need to overcome to progress along the translational research pathway? **Please summarise the critical hurdle within a sentence** and then expand to include further evidence to support your view.

*(Maximum 300 words)* |
|  |
| 1. Describe how you will use C4T funding to overcome the bottleneck including details about the project plan, the rationale, the hypothesis, main tasks, methodology - including analysis methods and sample size justification - and expected outcomes. *(Maximum 500 words)*
 |
|  |
| 1. What are the key milestones in overcoming the bottleneck? Please include timelines and how you will demonstrate they have been met? (Make use of Gantt charts if appropriate) *(Maximum 400 words)*
 |
|  |
| 1. Please identify any risks with the proposed approach and how these will be mitigated. Go/no go points can be identified on timeline / Gantt chart provided in question 9 (*Maximum 200 words*)
 |
|  |
| 1. Please outline a brief plan for follow on studies, potential industry collaborations and further funding, including targeted funding schemes and deadlines. If you do not have a clinical co-applicant please explain how you have/will gain clinical insight into the translational goals of the project *(Maximum 300 words)*
 |
|  |
| 1. Do you already have researchers in place to conduct this research?

**Yes [ ]  No [ ]**  | If **Yes**, please provide details, including their availability, and were possible a potential ‘back up’: |
|  |  |
|  | If **No**, please outline reasons and include a plan to source the researcher(s): |
|  |  |
| 1. Does your project include any cross-faculty and/or external organization involvement (including industry partnerships and NHS).

**Yes [ ]  No [ ]**  | *If* ***Yes****, please tick* ***and*** *specify below:* |
|  | *[ ]  Other Faculty* |  |
|  | *[ ]  NHS* |  |
|  | *[ ]  Industry* |  |
|  | *[ ]  Other* |  |
| 1. If you answered yes in **Q13**, will the external organization (EO) receive part of the funding and/or provide in kind contribution?

**Yes [ ]  No [ ]**  | *If* ***Yes****, please fill in the information below:* |
|  | *Name of the organisation:* |  |
|  | *Amount Allocated to EO:* |  |
|  | *In kind contribution from EO:* |  |
| 1. If you are proposing to collaborate with an SME or industry partner, have you been in contact with your faculty’s business engagement, and/or contracts teams?

**Yes [ ]  No [ ]**  | *If* ***Yes****, please name your contacts:* |
|  | *Business Engagement* |  |
|  | *Contracts:* |  |
| 1. Does your study require Home Office Animal License, NHS ethics & governance or any other approvals (e.g. access to data, tissue, software)?

**Yes [ ]  No [ ]**  | *If* ***Yes****, when and how will these be obtained? Please name any relevant contacts in BSF or Ethics and governance teams:* |
|  |  |
| 1. **OPTIONAL - BRC REMIT:** Only to be completed if your project aligns with BRC priorities (ticked boxes above). Project must sit across TWO clusters. Please describe how your project aligns with NIHR Manchester BRC strategic aims. (max 300 words).

*Please contact the BRC Funding manager, Lynsey Priest (**Lynsey.Priest@mft.nhs.uk**), if you have any questions regarding whether your project fits BRC remit.* |
|  |
| **Intellectual property (IP)** |
| Depending on whether the project will be funded by Wellcome, NIHR Manchester BRC or MRC budgets, different terms and conditions will apply. Wellcome awardees will be required to accept Wellcome’s standard revenue-and-equity sharing agreement as set out in [Wellcome’s grant conditions](https://wellcome.ac.uk/funding/guidance/grant-conditions). If funded by the BRC, awardees will be required to abide by the IP conditions of the BRC (see [application brief](http://documents.manchester.ac.uk/display.aspx?DocID=49136) for details). The Translation Manchester Team will notify successful applicants on which funder will support their projects if successful.If you have been in discussions with the Innovation Factory around this project, please name your contact below. We strongly encourage that you reach out to the Innovation Factory to complete this section of the application. |
| *Innovation Factory contact:* |  |
| *MFT R&I IP contact (if applicable):* |  |
| 1. Does the proposal have freedom to operate, or does it require access to background IP?
 |
|  |
| 1. Will the project generate new IP? If yes, how will this be managed?
 |
|   |
| 1. Will the project generate new IP that will be owned by an external party (e.g. external project partner)? If yes, how will this be managed?
 |
|  |

|  |
| --- |
| **Application Checklist** |
| [ ]  | I completed all questions of the C4T form |
| [ ]  | Any information that could identify me or my research group has **only** been included in the *PI details* page. |
| [ ]  | I have completed the Budget Sheet (last page of this document) and included the BlackDackel **project ID** and the **budget ID** relevant to this project. |
| [ ]  | I confirm that the information on BlackDackel matches the information added to the Budget Sheet. |
| [ ]  | *Only for projects involving small molecule drugs*: The project tractability section of the MRC DPFS small molecule information form is clearly covered in the main C4T application form, **OR** I have completed and attached the [MRC DPFS small molecule information form](https://documents.manchester.ac.uk/display.aspx?DocID=72629) to this application |
| [ ]  | I have deleted the first page of this document (i.e. description of the application process), and saved the rest of the file as PDF, using PI Name\_Surname as filename prior to submitting to translation@manchester.ac.uk.  |

**NOT TO BE SHARED EXTERNALLY**

**Confidence for Translation (C4T) Budget Sheet (Internal Applicants Only)**

The proposal needs to be costed through the University Research Costing Tool, guidance for this process can be found in [this document](https://documents.manchester.ac.uk/display.aspx?DocID=72594). Training is also available, see [FAQs](https://documents.manchester.ac.uk/display.aspx?DocID=72621).

*Please note, this funding is for Directly Incurred costs only, up to £75,000*

Project Title: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Lead PI Name: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Lead Collaborator/Expert Name (if applicable): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

|  |
| --- |
| **Project Costs** |
| **Directly Incurred (DI) costs**Please provide a detailed breakdown of all proposed costs. Staff costs should be obtained from BlackDackel. If you are costing existing members of staff, ensure to cost at the correct grade/spinal point and include their name if known. |
| **BlackDackel Information** |
| **Project ID** |  | **Budget ID** |  |
| **Cost type** | **Breakdown and description/detail** | **Cost (£)** |
| **Staff Costs**Include %FTE, start date and duration, name and grade of staff (if known) for each post costed |  |  |
| **Consumables**Provide full breakdown of consumables |  |  |
| **Other** \*(please specify) |  |  |
| **Total Costs:** |  |
| **PI and Co-Is Time commitment**Please provide details on the time you and your collaborator will dedicate to this project. This will be approved by your Head of School should your project be successful | **% FTE \*\*** |
|  |
| Principal Investigator |  |
| Co-Investigators |  |

**\****Please make sure that quotes for any bought in service* ***includes VAT*** *if applicable****\*\*****For each PI/Co-I please indicate the expected %FTE to be committed to this project. We do not need costs, just an indication of %FTE dedicated to this project.*

|  |  |
| --- | --- |
| This proposal is submitted by Principal Investigator: |  |
| (Date) | (Print name) | (Sign here) |